Literature DB >> 4401785

Chronic beta adrenergic blockade in arterial hypertension. Hemodynamic influences of dihydralazine and dynamic exercise and clinical effects of combined treatment.

R Sannerstedt, J Stenberg, A Vedin, C Wilhelmsson, L Werkö.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4401785     DOI: 10.1016/0002-9149(72)90176-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  16 in total

1.  Decrease in plasma noradrenaline levels following long-term treatment with prindolol in patients with essential hypertension.

Authors:  H M Brecht; F Banthien; W Schoeppe
Journal:  Klin Wochenschr       Date:  1976-11-15

Review 2.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

Review 3.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

4.  Clinical pharmacokinetics of hydrallazine.

Authors:  T Talseth
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

5.  A controlled study on the antihypertensive effect of a new beta-adrenergic receptor blocking drug, metoprolol, in combination with chlorthalidone.

Authors:  A Jäättelä; K Pyörälä
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

6.  Comparative study of alprenolol and methyldopa in previously untreated essential hypertension.

Authors:  J A Vedin; C E Wilhelmsson; L Werkö
Journal:  Br Heart J       Date:  1973-12

7.  Sympathetic reflex responses during treatment of essential hypertension with hydrallazine and oxprenolol.

Authors:  I B Davies; P S Sever; T Rosenthal
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

8.  Alpha- and beta-adrenergic receptor blockade in the treatment of hypertension.

Authors:  P A Majid; M K Meeran; M E Benaim; B Sharma; S H Taylor
Journal:  Br Heart J       Date:  1974-06

9.  Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.

Authors:  I Persson
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

10.  Hypotensive effect of oxprenolol in mild to moderate hypertension: a multicentre controlled study.

Authors:  M Motolese; G Muiesan; A Colombi
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.